The Asia-Pacific Lung Cancer Therapeutics Market was worth USD 1.09 billion in 2020 and estimated to be growing at a CAGR of 7.65%, to reach USD 1.58 billion by 2025.
Asia-Pacific countries such as India and China are the developing regions for the global lung cancer therapeutics market owing to the high occurrence of this disease along with growing healthcare alertness.
Lung cancer accounts for a greater share of the whole number of patients suffering from cancer. Small cell lung cancer type is dangerous due to the fact that there are no drugs present for its treatment and that the smaller size of cancer cells present in this type of cancer makes it harder to be treated even by surgical involvement.
The APAC lung cancer therapeutics market is expected to observe profitable growth in the coming years largely due to the stable increase in the occurrence of cancer cases. As the geriatric population is likely to increase, the incidence of lung cancer is predicted to rise, thus acting as a driver for revenue growth.
Lack of awareness among patients and side effects associated with the treatment therapies are expected to obstruct the growth of APAC lung cancer therapeutics market.
This research report on the APAC Lung Cancer Therapeutics Market is segmented and sub-segmented into the following categories:
By Treatment Type:
By Country:
Regionally, increasing the population base in countries like India and China is anticipated to increase the growth of this market in these areas.
The Top companies leading in the APAC Lung Cancer Therapeutics Market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmitKline, Eli Lilly and Company, Agennix AG, AstrazenecaPlc, and Sanofi-Aventis.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.1.1 Cisplatin
5.1.1.2 Taxol
5.1.1.3 Navelbine
5.1.1.4 Camptosar
5.1.1.5 Alimta
5.1.2 Radiotherapy
5.1.2.1 External Beam
5.1.2.2 Internal Beam
5.1.2.3 Systemic
5.1.3 Other Drugs
5.1.3.1 Abraxane
5.1.3.2 Avastin
5.1.3.3 Crizotinib
5.1.3.4 Docetaxel
5.1.3.5 Gefitinib
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 BoehringerIngelheim GmbH
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Hoffman-La Roche
9.3 Pfizer Inc.
9.4 GlaxoSmitKline
9.5 Eli Lilly and Company
9.6 AstrazenecaPlc
9.7 Sanofi-Aventis
9.8 Agennix AG
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
